{"Clinical Trial ID": "NCT00559845", "Intervention": ["INTERVENTION 1:", "Bevacizumab", "FEC, followed by paclitaxel, is administered in combination with bevacizumab for approximately 3 to 12 months.", "5-Fluorouracil 600 mg/m^2 i.v. bolus 15 min; epirubin 90 mg/m^2 i.v. 1 hour infusion; cyclophosphamide 600 mg/m^2 i.v. 1 hour infusion every 3 weeks for 4 cycles.", "Paclitaxel: 80 mg/m^2 i.v. more than one hour per week for 12 weeks.", "Bevacizumab: 10 mg/kg i.v. every 2 weeks for 6 cycles."], "Eligibility": ["Incorporation criteria:", ":: Female participants aged >=18;", "Stage III or inflammatory breast cancer;", "- positive or negative estrogen receptor/progesterone receptor (ER/PgR) and negative human epidermal growth factor receptor 2 (HER-2);", "- Left normal ventricular ejection fracture (VEF).", "- Exclusion criteria:", "- Prior chemotherapy/endocrinotherapy;", "Evidence of distant metastatic disease;", "Other primary tumours in the last 5 years (except for properly treated cancer in situ of the cervix, or basal cell skin cancer);", "Chronic daily treatment with > 325 milligrams of aspirin per day (mg/day) or > 75 mg/day of clopidogrel."], "Results": ["Performance measures:", "Percentage of participants with a complete pathological response as a result of the Principal Investigator review", "A complete pathological response was defined as the absence of invasive neoplastic cells during microscopic examination of tumour remains after surgery after primary systemic treatment.", "Time limit: Up to 7.5 years", "Results 1:", "Title of the arm/group: Bevacizumab", "Description of the arm/group: FEC, followed by paclitaxel, given in combination with bevacizumab for approximately 3-12 months.", "5-Fluorouracil 600 mg/m^2 i.v. bolus 15 min; epirubin 90 mg/m^2 i.v. 1 hour infusion; cyclophosphamide 600 mg/m^2 i.v. 1 hour infusion every 3 weeks for 4 cycles.", "Paclitaxel: 80 mg/m^2 i.v. more than one hour per week for 12 weeks.", "Bevacizumab: 10 mg/kg i.v. every 2 weeks for 6 cycles.", "Total number of participants analysed: 56", "Type of measurement: Number", "Unit of measure: percentage of participants 23.2"], "Adverse Events": ["Undesirable Events 1:", "Total: 8/54 (14.81 per cent)", "Anemia 1/54 (1.85%)", "Febrile Neutropenia 1/54 (1.85%)", "Hypertensive retinopathy 1/54 (1.85%)", "Febrile infection 1/54 (1.85%)", "Complication of postoperative wounds 1/54 (1.85%)", "Anormal 1/54 Cardiac Imaging Method (1.85%)", "In Situ 1/54 malignant melanoma (1.85%)", "Attempted suicide 1/54 (1.85%)", "Dyspnoea 1/54 (1.85%)"]}